Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 40.55
- Piotroski Score 3.00
- Grade Hold
- Symbol (PLSE)
- Company Pulse Biosciences, Inc.
- Price $17.65
- Changes Percentage (9.5%)
- Change $1.53
- Day Low $16.05
- Day High $17.71
- Year High $22.69
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.80
- Trailing P/E Ratio -15.47
- Forward P/E Ratio -15.47
- P/E Growth -15.47
- Net Income $-42,210,000
Income Statement
Quarterly
Annual
Latest News of PLSE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans
Investors may be drawn to unprofitable companies like Pulse Biosciences due to potential high returns. However, such companies can face bankruptcy if cash burn exceeds reserves. Pulse Biosciences had ...
By Yahoo! Finance | 1 week ago -
Pulse Biosciences Inc (PLSE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
Pulse Biosciences has made progress in treating Atrial Fibrillation using Nano PFA technology. Financially, they reported increased expenses in Q3 2024 but raised $60 million through a rights offering...
By Yahoo! Finance | 3 weeks ago -
A US$60m drop in the market cap of Pulse Biosciences, Inc. (NASDAQ:PLSE) is not what insiders like to see after purchasing shares recently
Insiders own 70% of Pulse Biosciences, showing a strong vested interest in the company's growth. Institutional investors hold a significant portion of the stock, adding credibility. While insider owne...
By Yahoo! Finance | 5 months ago
